Dense Deposit Disease Clinical Trial
Official title:
A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of complement activity, patients will enter into the Maintenance Period.The total treatment duration is up to 26 weeks.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04183101 -
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
|
Phase 2 | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Withdrawn |
NCT02302755 -
TP10 Use in Patients With C3 Glomerulopathy (C3G)
|
Phase 1 | |
| Active, not recruiting |
NCT05067127 -
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
| Active, not recruiting |
NCT05809531 -
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
| Terminated |
NCT03459443 -
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
|
Phase 2 | |
| Completed |
NCT03369236 -
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
|
Phase 2 | |
| Completed |
NCT01221181 -
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
|
Phase 1 | |
| Active, not recruiting |
NCT03453619 -
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
|
Phase 2 | |
| Completed |
NCT03723512 -
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
|
N/A | |
| Withdrawn |
NCT00583427 -
Sulodexide Treatment in Patients With Dense Deposit Disease
|
Phase 1 | |
| Completed |
NCT03124368 -
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
|
Phase 2 | |
| Available |
NCT04729062 -
C3G/Primary IC-MPGN EAP
|